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Inhibiting Axon Degeneration and Synapse Loss
Attenuates Apoptosis and Disease Progression
in a Mouse Model of Motoneuron Disease
ron disease; the mutation was recently localized to a
tubulin chaperone E gene [3, 4].
Hindlimb atrophy and muscle weakness were evident
at 2 weeks of age in pmn/pmn mice, and all mice died
at approximately 40 days of age (40.5  0.7, n  11). In
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show a declining ability to preserve neuromuscular func-
tion following nerve damage in mice 1 month old [13].
Because the Wlds and pmn mutants were maintained
Summary in different strains (C57BL/6 and 129Svj, respectively),
we also assessed offspring of Wlds  129Svj and of
Apoptosis is a hallmark of motoneuron diseases such (pmn  C57BL/6)  (pmn  C57BL/6) matings; disease
as amyotrophic lateral sclerosis (ALS) and spinal mus- progression in pmn/pmn mice and survival of axotom-
cular atrophy (SMA) [1]. In a widely used mouse model ized neurons in Wlds mice were not significantly affected
of motoneuron disease (progressive motor neuronopa- by genetic background (data not shown). We also com-
thy or pmn) [2–4], transgenic expression of the anti- pared pmn/pmn mice carrying one or two copies of the
apoptotic bcl-2 gene [5] or treatment with glial cell- Wlds gene (that is, Wlds heterozygotes and homozy-
derived neurotrophic factor [6] prevents the apoptosis gotes) but found no gene dosage effect.
of the motoneuron soma; however, they were unable The best characterized effect of the Wlds gene prod-
to affect the life span of the animals. The goal of the uct is its ability to delay Wallerian degeneration. To de-
present work was to determine whether the pmn phe- termine whether it exerts this effect on motor axons in
notype could be rescued by means of a gene that pmn/pmn mice, we counted myelinated axons in the
inhibits axon degeneration. For this reason, the pmn phrenic motor nerve. The number of axons was signifi-
mice were crossed with mice bearing the dominant cantly lower in pmn/pmn than in control nerves by post-
Wlds (“slow Wallerian degeneration”) mutation, which natal day 15 (P15) and was reduced 47% by P30. In
slows axon degeneration and synapse loss [7–9]. We contrast, no axon loss was apparent in pmn/pmn;Wlds
show here that the Wlds gene product attenuates mice at P30, and even P50 pmn/pmn;Wlds phrenic
symptoms, extends life span, prevents axon degener- nerves retained more axons than did P30 pmn/pmn
ation, rescues motoneuron number and size, and de- phrenic nerves (Figures 2A–2D). The Wlds gene also
lays retrograde transport deficits in pmn/pmn mice. rescued pmn/pmn axons in a cranial motor nerve, the
These results suggest new pathogenic mechanisms facial (see Table S1 in the Supplemental Data available
and therapeutic avenues for motoneuron diseases. with this article online). These results indicate that Wlds
delays degeneration of motor axons by 1 week.
If apoptosis of motoneurons in pmn/pmn mice is aResults and Discussion
secondary consequence of axon degeneration, the
presence of the Wlds gene might slow or decrease theIn Wlds mice, a genomic triplication leads to generation
loss. To test this idea, we counted gastrocnemiusof a fusion protein in which the amino terminus of the
motoneurons in the lumbar spinal cord and hindbrainubiquitination factor E4b is fused to the enzyme nicotin-
motoneurons in four cranial nuclei (trochlear, trigeminal,amide mononucleotide adenylyl transferase (Nmnat) [9].
facial, and hypoglossal). Cranial pools were identifiableWhen expressed from the mutant locus or as a trans-
because of their sharp boundaries; gastrocnemiusgene, the Wlds protein delays neuromuscular failure and
motoneurons were selectively labeled by retrogradeaxon degeneration following nerve injury, but it does not
transport following injection of fluorogold into the gas-directly block apoptosis [7–9]. Here, we asked whether
trocnemius muscle (Figures 2E–2G and 2I–2K). Oddly,C57BL/Wlds mice could affect the disease progression
trigeminal motoneurons were largely spared in pmn/in pmn/pmn mice. pmn is a naturally occurring recessive
pmn mice. In the other three populations, however,mutant that has been much used as a model of motoneu-
motoneuron number decreased progressively in pmn/
pmn mice. The Wlds gene protected motoneurons al-
most completely at P30 and P40 and, to a considerable*Correspondence: ann.kato@medecine.unige.ch
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Figure 1. The Wlds Gene Product Extends Life Span and Improves Motor Function in pmn/pmn Mice
(A) Survival of pmn/pmn (n  11) and pmn/pmn;Wlds mice (n  12). The mean survival time of pmn/pmn;Wlds mice (bold line) is significantly
increased (50%) compared to pmn/pmn mice (thin line) (p  0.0001).
(B–D) Motor performance of control, pmn/pmn, and pmn/pmn;Wlds mice. The percentage of animals that successfully passed the tests is
expressed as a function of age [10, 12]. (B) In this panel, the data show the performance of mice crossing a horizontal circular bar. (C) In this
panel, the data show the performance of mice climbing an inclined plane at an angle of 30. (D) In this panel, the data show the stride length
of mice (n  8 in each group and at each time; average  SEM).
extent, even at P50 (Figure 2H and Table S2 in Supple- cular integrity, we compared neuromuscular junctions
in pmn/pmn and pmn/pmn;Wlds mice. By P30, nearlymental Data). Likewise, Wlds attenuated the atrophy of
motoneurons seen in the pmn/pmn facial pool (Figures a third of synaptic sites were denervated in pmn/pmn
tibialis muscle, which is innervated by motoneurons in2I–2L). These results raise the possibility that rescue of
motoneuron number and size is a consequence of axo- lumbar segments (Figures 4B and 4C and Table 1). In
that surviving motoneurons may sprout, this figure isnal preservation.
How might axonal pathology in pmn/pmn mice lead concordant with the 39% motoneuron loss at this age.
An additional third of the nerve terminals showed signsto motoneuronal death? One possibility is that a deficit
in axonal transport causes motoneuron degeneration, of damage, such as swollen mitochondria and clumped
vesicles (Figures 4B and 4C), suggesting that synapticas has been suggested for ALS [14, 15]. Indeed, we
showed previously that the rate of retrograde axonal defects precede frank denervation. In pmn/pmn;Wlds
mice, in contrast, 10% of synaptic profiles exhibitedtransport is slowed in pmn/pmn mice [11]. To determine
whether Wlds could correct this defect, we measured denervation, and 3/4 were similar in morphology to
those in control (wild-type, pmn/, or Wlds) musclesthe accumulation of a retrograde tracer in motoneurons
following injection into muscle. The rate of retrograde (Figures 4A and 4D and Table 1). Thus, the incidence
of synaptic pathology was twice as great in pmn/pmntransport of fluorogold was slower in pmn/pmn mice
at P15 and preceded the onset of soma degeneration mutants as in pmn/pmn;Wlds mice; this finding provides
a cellular basis for the behavioral improvement docu-(Figures 3A–3C). The presence of the Wlds allele rescued
retrograde transport of fluorogold completely at P15 and mented above.
Together, our data demonstrate the ability of the WldsP30 and significantly at P40. Thus, Wlds affects not only
the integrity of the myelinated axons, but it also protects protein to postpone axon degeneration, preserve neuro-
muscular structure, delay transport or uptake defects,against impaired axonal transport, diminished axonal
uptake, or reduced numbers of axons transporting the attenuate symptoms, and extend life span in mice with
a “dying back” motoneuronopathy. In contrast, the anti-tracer molecule, all of which represent important com-
ponents of axon metabolism. apoptotic protein, bcl-2, rescues cell bodies but has
minimal effects on axons or disease progression [5].Finally, because the proximate cause of symptoms in
pmn/pmn mice, as in ALS and SMA, is loss of neuromus- Five implications of these results are as follows. First,
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Figure 2. Effect of the Wlds Gene Product on Motor Axons and Motoneurons in pmn/pmn Mice
(A–L) Loss of (A–D) motor axons, (E–H) motoneurons, and (I–L) atrophy of motoneurons in pmn/pmn mice are all attenuated by Wlds. (A–C)
Micrographs of cross-sections of the phrenic nerve from (A) control, (B) pmn/pmn, and (C) pmn/pmn;Wlds mice at P30. (D) Number of
myelinated phrenic axons at different ages. (E–G) A transverse section of lumbar spinal cord from (E) control, (F) pmn/pmn, and (G) pmn/
pmn;Wlds mice at P30. Motoneurons were labeled by injecting fluorogold into the gastrocnemius muscle; 4 days later, the animals were fixed
and the lumbar spinal cord was sectioned at 30 m [11]. (H) Number of fluorogold-labeled motoneurons at different ages. (I–K) Micrographs
of the facial nucleus in (I) control, (J) pmn/pmn, and (K) pmn/pmn;Wld mice. (L) Size of facial motoneuron cell bodies at P30. (C, control; W/W,
Wlds homozygote; p/p, pmn/pmn; p/p;W, pmn/pmn;Wlds). In all of these experiments, the p values were 0.001 when comparing the controls
to the experimental animals. The triangles represent control mice, the circles represent pmn/pmn mice, and the squares represent pmn/
pmn;Wlds mice. The scale bar represents 50 m in (A)–(C) and (I)–(K) and 100 m in (D)–(F).
because the Wlds gene does not prevent apoptosis of ron number and size by Wlds is a consequence of axonal
preservation. Second, in view of increasing evidencethe cell body [16], and because bcl-2 does not prevent
axon degeneration, we suggest that rescue of motoneu- that degeneration of axons and apoptosis occur by dis-
Figure 3. Effect of the Wlds Gene Product on Fluorogold Retrolabelling of Motoneurons in pmn/pmn Mice at Different Ages
(A–C) Retrograde labeling of lumbar motoneurons projecting into the gastrocnemius muscle. Injection of fluorogold was performed at (A) P15,
(B) P30, and (C) P40. The labeled motoneurons were counted on serial sections at 24, 48, and 96 hr in the lumbar spinal cord. (n  5). At P15
and P30, the p values were0.001 when comparing the controls to pmn/pmn and pmn/pmn;Wlds to pmn/pmn. At P40, the p values were0.001
when comparing the controls to pmn/pmn and 0.01 when comparing the controls to pmn/pmn;Wlds.
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Figure 4. The Wlds Gene Product Attenuates Pathology of Neuromuscular Junctions in pmn/pmn Mice
(A–D) Neuromuscular junctions from tibialis muscles of (A) control, (B and C) pmn/pmn, and (D) pmn/pmn;Wlds mice at P30. Electron microscopy
was performed as described in [20]. Control nerve terminals are vesicle laden. Nerve terminals are nearly withdrawn from some synaptic sites
(arrow in [C]) in pmn/pmn mice, and terminals show signs of damage, such as swollen mitochondria, in others. (D) The presence of Wlds
attenuates synaptic pathology. See text for quantitation. The scale bar represents 1 m.
tinct mechanisms [7, 8, 16, 17], we suggest that pmn/ reported to date [5, 6, 10], suggesting that it may offer
a new approach for the therapy of motoneuron diseasespmn and, by extension, some forms of ALS or SMA may
involve primary axonal or terminal pathology and that and other neurodegenerative disorders characterized
by axon degeneration.the pathways of axon degeneration in disease and injury
overlap. Third, effects of the trophic factors ciliary neu-
Supplemental Datarotrophic factor (CNTF) [10] and glial cell-derived neuro-
Supplemental Data including the Experimental Procedures and Ta-trophic factor (GDNF) [6] on pmn/pmn mice resemble
bles S1 and S2 are available at http://images.cellpress.com/supmat/in some respects those of Wlds and bcl-2 [5], respec-
supmatin.htm.
tively; this resemblance suggests that, in addition to the
known anti-apoptotic effects of both trophic factors,
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Table 1. Synaptic Profiles in Tibialis Muscles of Controls, pmn/pmn, and pmn/pmn;Wlds Mice at 30 Days of Age
Number of
Genotype Normal Damaged Denervated Synapses Analyzed
Control 96% 4% 0% 52
pmn/pmn 36% 34% 29% 134
pmn/pmn;Wlds 72% 22% 6% 105
Percentage of synaptic sites in cross-sections of tibialis muscles at 30 days of age in control (n  3), pmn/pmn (n  4), and pmn/pmn;Wlds
mice (n  3). The number of synapses in pmn/pmn;Wlds mice was significantly greater than in pmn/pmn mice.
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